{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:36:16Z","timestamp":1793795776757,"version":"4.6.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Cancer patients are more likely to develop and die of bloodstream infection (BSI) than noncancer patients. Methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA), which is associated with immense mortality and economic burden worldwide, is not covered by the recommended initial antibiotic therapy for cancer patients with BSI. This systemic review was performed to estimate the global methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) prevalence among bacteremia in patients with malignancy, and further study the predictors and mortality of cancer patients with MRSA bacteremia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PubMed and EMBASE databases were searched for studies published from Jan. 2000 to Mar. 2020 that provided primary data on the prevalence, predictors, or mortality of MRSA bacteremia in cancer patients. A random-effects model meta-analysis was performed to estimate the pooled prevalence of MRSA with 95% confidence intervals (95% CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The pooled prevalence of MRSA was 3% (95% CI 2\u20135%) among all bloodstream infections (BSIs) and 44% (95% CI 32\u201357%) among\n                      <jats:italic>S. aureus<\/jats:italic>\n                      bacteremia in cancer patients. Based on geographical stratification, the pooled prevalence was 5% in Africa (95% CI 1\u201314%), 1% in Americas (95% CI 1\u20132%), 2% in Europe (95% CI 1\u20134%), 4% in Western Pacific (95% CI 2\u20137%), 8% in South-east Asia (95% CI 4\u201314%) and 0% in Eastern Mediterranean (95% CI 0\u20133%). No significant temporal change in MRSA rates was detected in this analysis (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.06;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.24). Predictors for MRSA BSIs among cancer patients were identified by comparison with their methicillin-susceptible counterparts, and they were mainly related to healthcare-associated infections and immunosuppression. Finally, the 60-day mortality in adult cancer patients with MRSA BSIs was reported to be 12%, and the 6-month overall mortality was 43.2%, with community-onset infection, secondary BSI, and vancomycin MIC\u22652\u2009g\/mL being the risk factors for mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the prevalence of MRSA BSIs among cancer patients is relatively low, it did not decline over time as MRSA BSIs in the general hospital population and the high mortality rate was related to MRSA BSIs in patients with malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05763-y","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T08:02:53Z","timestamp":1610611373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhouqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"issue":"9","key":"5763_CR1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/cncr.20218","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH, Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. (2004) 100(2):228-37. Cancer. 2004;100(9):1993\u20134.","journal-title":"Cancer."},{"issue":"15","key":"5763_CR2","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1200\/JCO.2002.11.135","volume":"20","author":"LJ Walshe","year":"2002","unstructured":"Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among Cancer patients with peripherally inserted central catheters. J Clin Oncol. 2002;20(15):3276\u201381.","journal-title":"J Clin Oncol"},{"key":"5763_CR3","doi-asserted-by":"crossref","unstructured":"Hsieh RW, Schrank GM, Hsu WT, Su KY, Lee CC. Temporal trend of microbiological profiles among patients with bloodstream infections: A comparison between cancer and noncancer patients in a nationwide database. J Clin Oncol. 2019;37.","DOI":"10.1200\/JCO.2019.37.15_suppl.e13078"},{"issue":"1","key":"5763_CR4","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1007\/s00520-018-4298-7","volume":"27","author":"F Macedo","year":"2019","unstructured":"Macedo F, Monteiro AR, Soares R, Pereira T, Bonito N, Sousa G. Bacteremia in oncologic patients and multi drug resistant microorganisms: A growing issue. Support Care Cancer. 2019;27(1):S139.","journal-title":"Support Care Cancer"},{"key":"5763_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2018.03.022","volume":"71","author":"B Islas-Munoz","year":"2018","unstructured":"Islas-Munoz B, Volkow-Fernandez P, Ibanes-Gutierrez C, Villamar-Ramirez A, Vilar-Compte D, Cornejo-Juarez P. Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J Infect Dis. 2018;71:59\u201364.","journal-title":"Int J Infect Dis"},{"key":"5763_CR6","doi-asserted-by":"crossref","unstructured":"Thomer L, Schneewind O, Missiakas D. Pathogenesis of Staphylococcus aureus Bloodstream Infections. In: Abbas AK, Aster JC, Galli SJ, editors. Annu Rev Pathol, Vol 11. Annual Review of Pathology-Mechanisms of Disease. 2016;11. p. 343\u2013364.","DOI":"10.1146\/annurev-pathol-012615-044351"},{"key":"5763_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/s12879-014-0580-6","volume":"14","author":"S McNicholas","year":"2014","unstructured":"McNicholas S, Talento AF, O'Gorman J, Hannan MM, Lynch M, Greene CM, et al. Cytokine responses to Staphylococcus aureus bloodstream infection differ between patient cohorts that have different clinical courses of infection. BMC Infect Dis. 2014;14:580.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"5763_CR8","first-page":"493","volume":"49","author":"E J, J L, R H, P R, H H, R V","year":"2017","unstructured":"E J, J L, R H, P R, H H, R V, et al. Comparison of outcome and clinical characteristics of bacteremia caused by methicillin-resistant, penicillin-resistant and penicillin-susceptible Staphylococcus aureus strains. Infect Dis (London, England). 2017;49(7):493\u2013500.","journal-title":"Infect Dis (London, England)"},{"key":"5763_CR9","first-page":"S11","volume":"28","author":"D Kobayashi","year":"2013","unstructured":"Kobayashi D, Yokota K, Takahashi O, Arioka H, Fukui T, Wee CC. A prediction rule for mortality for inpatients with staphylococcus aureus bacteremia: A classification and regression tree (CART) analysis. J Gen Intern Med. 2013;28:S11.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"5763_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1086\/377540","volume":"37","author":"S-H Kim","year":"2003","unstructured":"Kim S-H, Park W-B, Lee K-D, Kang C-I, Kim H-B, M-d O, et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis. 2003;37(6):794\u20139.","journal-title":"Clin Infect Dis"},{"key":"5763_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijid.2017.05.010","volume":"61","author":"P Ayau","year":"2017","unstructured":"Ayau P, Bardossy AC, Sanchez G, Ortiz R, Moreno D, Hartman P, et al. Risk factors for 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infections. Int J Infect Dis. 2017;61:3\u20136.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"5763_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/infdis\/jit501","volume":"209","author":"MS Calderwood","year":"2014","unstructured":"Calderwood MS, Desjardins CA, Sakoulas G, Nicol R, Dubois A, Delaney ML, et al. Staphylococcal enterotoxin P predicts bacteremia in hospitalized patients colonized with methicillin-resistant staphylococcus aureus. J Infect Dis. 2014;209(4):571\u20137.","journal-title":"J Infect Dis"},{"issue":"10","key":"5763_CR13","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s00520-011-1353-z","volume":"20","author":"CI Kang","year":"2012","unstructured":"Kang CI, Song JH, Chung DR, Peck KR, Yeom JS, Son JS, et al. Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer. 2012;20(10):2371\u20138.","journal-title":"Support Care Cancer"},{"issue":"6","key":"5763_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.eimc.2009.06.015","volume":"28","author":"SI Cuervo","year":"2010","unstructured":"Cuervo SI, Cort\u00e9s JA, S\u00e1nchez R, Rodr\u00edguez JY, Silva E, Tibavizco D, et al. Risk factors for mortality caused by Staphylococcus aureus bacteremia in cancer patients. Enferm Infecc Microbiol Clin. 2010;28(6):349\u201354.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"10","key":"5763_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/j.1462-5822.2012.01832.x","volume":"14","author":"M Otto","year":"2012","unstructured":"Otto M. MRSA virulence and spread. Cell Microbiol. 2012;14(10):1513\u201321.","journal-title":"Cell Microbiol"},{"issue":"1","key":"5763_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/13543784.2016.1109077","volume":"25","author":"C Vuong","year":"2016","unstructured":"Vuong C, Yeh AJ, Cheung GY, Otto M. Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs. 2016;25(1):73\u201393.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"5763_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1469-0691.2011.03679.x","volume":"18","author":"M Bassetti","year":"2012","unstructured":"Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M, et al. Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2012;18(9):862\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"5763_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0953-6205(01)00189-3","volume":"13","author":"D Talon","year":"2002","unstructured":"Talon D, Woronoff-Lemsi MC, Limat S, Bertrand X, Chatillon M, Gil H, et al. The impact of resistance to methicillin in Staphylococcus aureus bacteremia on mortality. Eur J Intern Med. 2002;13(1):31\u20136.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"5763_CR19","first-page":"299","volume":"61","author":"C-I Kang","year":"2010","unstructured":"Kang C-I, Song J-H, Chung DR, Peck KR, Ko KS, Yeom J-S, et al. Clinical impact of methicillin resistance on outcome of patients with Staphylococcus aureus infection: a stratified analysis according to underlying diseases and sites of infection in a large prospective cohort. J Inf Secur. 2010;61(4):299\u2013306.","journal-title":"J Inf Secur"},{"issue":"12","key":"5763_CR20","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/jac\/dkq373","volume":"65","author":"M Paul","year":"2010","unstructured":"Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65(12):2658\u201365.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"5763_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.idc.2016.02.009","volume":"30","author":"M H, L M, S D","year":"2016","unstructured":"M H, L M, S D. Bacteremia due to methicillin-resistant Staphylococcus aureus: new therapeutic approaches. Infect Dis Clin N Am. 2016;30(2):491\u2013507.","journal-title":"Infect Dis Clin N Am"},{"issue":"7","key":"5763_CR22","doi-asserted-by":"publisher","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","volume":"14","author":"LR Baden","year":"2016","unstructured":"Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of Cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(7):882\u2013913.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"5763_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"5763_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ijantimicag.2017.07.003","volume":"50","author":"M Alevizakos","year":"2017","unstructured":"Alevizakos M, Gaitanidis A, Andreatos N, Arunachalam K, Flokas ME, Mylonakis E. Bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;50(5):657\u201363.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"5763_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","volume":"32","author":"E Montassier","year":"2013","unstructured":"Montassier E, Batard E, Gastinne T, Potel G, Cocheti\u00e8re MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32(7):841\u201350.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5763_CR26","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 11 Apr 2020."},{"issue":"3","key":"5763_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"11","key":"5763_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","volume":"67","author":"JJ Barendregt","year":"2013","unstructured":"Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974\u20138.","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"5763_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jmii.2011.01.035","volume":"44","author":"CC Huang","year":"2011","unstructured":"Huang CC, Wu CJ, Wang LR, Lee HC, Chang CM, Lee NY, et al. Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan. J Microbiol Immunol Infect. 2011;44(5):376\u201381.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"5763_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s13104-019-4520-9","volume":"12","author":"M Lubwama","year":"2019","unstructured":"Lubwama M, Phipps W, Najjuka CF, Kajumbula H, Ddungu H, Kambugu JB, et al. Bacteremia in febrile cancer patients in Uganda. BMC Res Notes. 2019;12(1):464.","journal-title":"BMC Res Notes"},{"issue":"3","key":"5763_CR31","first-page":"197","volume":"36","author":"H-P Lai","year":"2003","unstructured":"Lai H-P, Hsueh P-R, Chen Y-C, Lee P-I, Lu C-Y, Lu M-Y, et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect. 2003;36(3):197\u2013202.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"5763_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ijid.2007.02.002","volume":"11","author":"ND Baskaran","year":"2007","unstructured":"Baskaran ND, Gan GG, Adeeba K, Sam IC. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. Int J Infect Dis. 2007;11(6):513\u20137.","journal-title":"Int J Infect Dis"},{"issue":"2\u20133","key":"5763_CR33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000085623","volume":"51","author":"F-D Wang","year":"2005","unstructured":"Wang F-D, Lin M-L, Liu C-Y. Bacteremia in patients with hematological malignancies. Chemotherapy. 2005;51(2\u20133):147\u201353.","journal-title":"Chemotherapy."},{"issue":"9","key":"5763_CR34","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00520-013-1797-4","volume":"21","author":"KGE Miedema","year":"2013","unstructured":"Miedema KGE, Winter RHLJ, Ammann RA, Droz S, Spanjaard L, de Bont ESJM, et al. Bacteria causing bacteremia in pediatric cancer patients presenting with febrile neutropenia-species distribution and susceptibility patterns. Support Care Cancer. 2013;21(9):2417\u201326.","journal-title":"Support Care Cancer"},{"issue":"6","key":"5763_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1469-0691.2004.00874.x","volume":"10","author":"E Velasco","year":"2004","unstructured":"Velasco E, Byington R, Martins CSA, Schirmet M, Dias LCM, Gon\u00e7alves VMSC. Bloodstream infection surveillance in a cancer Centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect. 2004;10(6):542\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"5763_CR36","doi-asserted-by":"publisher","first-page":"CR304","DOI":"10.12659\/MSM.881773","volume":"17","author":"ES Horasan","year":"2011","unstructured":"Horasan ES, Ersoz G, Tombak A, Tiftik N, Kaya A. Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients. Med Sci Monit. 2011;17(5):CR304\u2013CR9.","journal-title":"Med Sci Monit"},{"issue":"3","key":"5763_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0971-5851.190352","volume":"37","author":"G Bhat","year":"2016","unstructured":"Bhat G, Babu K, Lokanatha D, Lakshmaiah KC, Suresh Babu MC, Jacob L, et al. Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: A timeline of clinical and microbial trends through the years. Indian J Med Paediatr Oncol. 2016;37(3):174.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"5763_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijid.2018.09.012","volume":"77","author":"T Mvalo","year":"2018","unstructured":"Mvalo T, Eley B, Bamford C, Stanley C, Chagomerana M, Hendricks M, et al. Bloodstream infections in oncology patients at red cross war memorial Children\u2019s hospital, Cape Town, from 2012 to 2014. Int J Infect Dis. 2018;77:40\u20137.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"5763_CR39","first-page":"39","volume":"28","author":"M Yamamoto","year":"2010","unstructured":"Yamamoto M, Shiono Y, Suzuki I, Kouno K, Hiroshima Y, Kato Y, et al. Bloodstream infections in patients with hematological malignancies at the adult hematology ward of Yamagata University hospital. Yamagata Med J. 2010;28(2):39\u201349.","journal-title":"Yamagata Med J"},{"key":"5763_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/TCRM.S68450","volume":"10","author":"H Gedik","year":"2014","unstructured":"Gedik H, Simsek F, Kanturk A, Yildirmak T, Arica D, Aydin D, et al. Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens? Ther Clin Risk Manag. 2014;10:743\u201352.","journal-title":"Ther Clin Risk Manag"},{"key":"5763_CR41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s13104-015-1701-z","volume":"8","author":"N Obeng-Nkrumah","year":"2015","unstructured":"Obeng-Nkrumah N, Labi AK, Acquah ME, Donkor ES. Bloodstream infections in patients with malignancies: implications for antibiotic treatment in a Ghanaian tertiary setting. BMC Res Notes. 2015;8:742.","journal-title":"BMC Res Notes"},{"issue":"2","key":"5763_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s15010-004-3049-5","volume":"32","author":"M Anatoliotaki","year":"2004","unstructured":"Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, et al. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection. 2004;32(2):65\u201371.","journal-title":"Infection."},{"issue":"1","key":"5763_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijid.2003.11.010","volume":"9","author":"H El-Mahallawy","year":"2005","unstructured":"El-Mahallawy H, Sidhom I, El-Din NHA, Zamzam M, El-Lamie MM. Clinical and microbiologic determinants of serious bloodstream infections in Egyptian pediatric cancer patients: A one-year study. Int J Infect Dis. 2005;9(1):43\u201351.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"5763_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijantimicag.2016.11.009","volume":"49","author":"C-Y Chen","year":"2017","unstructured":"Chen C-Y, Tien F-M, Sheng W-H, Huang S-Y, Yao M, Tang J-L, et al. Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical Centre in northern Taiwan, 2008-2013. Int J Antimicrob Agents. 2017;49(3):272\u201381.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"5763_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3947\/ic.2013.45.1.51","volume":"45","author":"J-C Kwon","year":"2013","unstructured":"Kwon J-C, Kim S-H, Choi J-K, Cho S-Y, Park Y-J, Park SH, et al. Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the Catholic blood and marrow transplantation center. Infect Chemother. 2013;45(1):51.","journal-title":"Infect Chemother"},{"issue":"10","key":"5763_CR46","first-page":"686","volume":"47","author":"\u00d6 Kara","year":"2015","unstructured":"Kara \u00d6, Zarakolu P, A\u015f\u00e7io\u011flu S, Etg\u00fcl S, Uz B, B\u00fcy\u00fcka\u015fik Y, et al. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis (London, England). 2015;47(10):686\u201393.","journal-title":"Infect Dis (London, England)"},{"issue":"3","key":"5763_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00520-013-2012-3","volume":"22","author":"M Bodro","year":"2014","unstructured":"Bodro M, Gudiol C, Garcia-Vidal C, Tubau F, Contra A, Boix L, et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Support Care Cancer. 2014;22(3):603\u201310.","journal-title":"Support Care Cancer"},{"issue":"6","key":"5763_CR48","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/jac\/dkt002","volume":"68","author":"S Schelenz","year":"2013","unstructured":"Schelenz S, Nwaka D, Hunter PR. Longitudinal surveillance of bacteraemia in haematology and oncology patients at a Uk cancer Centre and the impact of ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother. 2013;68(6):1431\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"5763_CR49","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.2147\/IDR.S168867","volume":"11","author":"B Arega","year":"2018","unstructured":"Arega B, Woldeamanuel Y, Adane K, Sherif AA, Asrat D. Microbial spectrum and drug-resistance profile of isolates causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia. Infect Drug Resist. 2018;11:1511\u20139.","journal-title":"Infect Drug Resist"},{"issue":"6","key":"5763_CR50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ijantimicag.2005.01.020","volume":"25","author":"D Greenberg","year":"2005","unstructured":"Greenberg D, Moser A, Yagupsky P, Peled N, Hofman Y, Kapelushnik J, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents. 2005;25(6):469\u201373.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"5763_CR51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/INF.0b013e3181b9a363","volume":"29","author":"A Srinivasan","year":"2010","unstructured":"Srinivasan A, Seifried S, Zhu L, Srivastava DK, Flynn PM, Bankowski MJ, et al. Staphylococcus aureus bacteremia in pediatric patients with cancer. Pediatr Infect Dis J. 2010;29(2):172\u20134.","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"5763_CR52","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1007\/s00520-018-4275-1","volume":"26","author":"OY Bello-Chavolla","year":"2018","unstructured":"Bello-Chavolla OY, Bahena-Lopez JP, Garciadiego-Fosass P, Volkow P, Garcia-Horton A, Velazquez-Acosta C, et al. Bloodstream infection caused by S. aureus in patients with cancer: a 10-year longitudinal single-center study. Support Care Cancer. 2018;26(12):4057\u201365.","journal-title":"Support Care Cancer"},{"issue":"10","key":"5763_CR53","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1634\/theoncologist.2012-0029","volume":"17","author":"SN Mahajan","year":"2012","unstructured":"Mahajan SN, Shah JN, Hachem R, Tverdek F, Adachi JA, Mulanovich V, et al. Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist. 2012;17(10):1329\u201336.","journal-title":"Oncologist"},{"issue":"3","key":"5763_CR54","first-page":"143","volume":"93","author":"M Mar\u00edn","year":"2014","unstructured":"Mar\u00edn M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratal\u00e0 J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (United States). 2014;93(3):143\u20139.","journal-title":"Medicine (United States)"},{"issue":"3","key":"5763_CR55","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/jac\/dks512","volume":"68","author":"EJ B","year":"2013","unstructured":"EJ B. There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother. 2013;68(3):492\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"5763_CR56","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56\u201393.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"5763_CR57","doi-asserted-by":"publisher","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","volume":"68","author":"AP Kourtis","year":"2019","unstructured":"Kourtis AP, Hatfield K, Baggs J, Mu Y, See I, Epson E, et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections - United States. MMWR Morb Mortal Wkly Rep. 2019;68(9):214\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"5763_CR58","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/14787210.2016.1236684","volume":"14","author":"K H, DR C","year":"2016","unstructured":"K H, DR C. Changing epidemiology of community-associated methicillin-resistant Staphylococcus aureus in the Asia-Pacific region. Expert Rev Anti-Infect Ther. 2016;14(11):1007\u201322.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"3","key":"5763_CR59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/jac\/dkf126","volume":"50","author":"M Tumbarello","year":"2002","unstructured":"Tumbarello M, de Gaetano DK, Tacconelli E, Citton R, Spanu T, Leone F, et al. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. J Antimicrob Chemother. 2002;50(3):375\u201382.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"5763_CR60","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1017\/S0950268818001255","volume":"146","author":"YM Wi","year":"2018","unstructured":"Wi YM, Rhee JY, Kang CI, Chung DR, Song JH, Peck KR. Clinical predictors of methicillin-resistance and their impact on mortality associated with Staphylococcus aureus bacteraemia. Epidemiol Infect. 2018;146(10):1326\u201336.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"5763_CR61","first-page":"449","volume":"61","author":"JT Wang","year":"2010","unstructured":"Wang JT, Wang JL, Fang CT, Chie WC, Lai MS, Lauderdale TL, et al. Risk factors for mortality of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: with investigation of the potential role of community-associated MRSA strains. J Inf Secur. 2010;61(6):449\u201357.","journal-title":"J Inf Secur"},{"issue":"2","key":"5763_CR62","first-page":"131","volume":"58","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2009","unstructured":"Rodr\u00edguez-Ba\u00f1o J, Mill\u00e1n AB, Dom\u00ednguez MA, Borraz C, Gonz\u00e1lez MP, Almirante B, et al. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus. J Inf Secur. 2009;58(2):131\u20137.","journal-title":"J Inf Secur"},{"issue":"6","key":"5763_CR63","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/jac\/dkt016","volume":"68","author":"O G, M C, MA D, B P, V P, B A","year":"2013","unstructured":"O G, M C, MA D, B P, V P, B A, et al. Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2013;68(6):1423\u201330.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"5763_CR64","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/MD.0b013e318030d344","volume":"86","author":"GA Ghanem","year":"2007","unstructured":"Ghanem GA, Boktour M, Warneke C, Pham-Williams T, Kassis C, Bahna P, et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients - high rate of complications with therapeutic implications. Medicine. 2007;86(1):54\u201360.","journal-title":"Medicine."},{"issue":"2","key":"5763_CR65","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijantimicag.2012.04.003","volume":"40","author":"YM Wi","year":"2012","unstructured":"Wi YM, Kim JM, Joo EJ, Ha YE, Kang CI, Ko KS, et al. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2012;40(2):108\u201313.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"5763_CR66","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/1469-0691.12108","volume":"19","author":"O G, M C, MA D, B P, V P, B A, et a","year":"2013","unstructured":"O G, M C, MA D, B P, V P, B A, et al. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2013;19(11):1049\u201357.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05763-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T08:07:18Z","timestamp":1610611638000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05763-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5763"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05763-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-38902\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38902\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-38902\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}